Dual inhibition of human type 4 phosphodiesterase isostates by (R*,R*)-(±)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate

被引:3
作者
Tian, GC [1 ]
Rocque, WJ
Wiseman, JS
Thompson, IZ
Holmes, WD
Domanico, PL
Stafford, JA
Feldman, PL
Luther, MA
机构
[1] Glaxo Wellcome Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA
[2] Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA
[3] Glaxo Wellcome Inc, Dept Med Chem, Res Triangle Pk, NC 27709 USA
[4] Glaxo Wellcome Inc, Div Res Informat Resources, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1021/bi972700v
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purified recombinant human type 4 phosphodiesterase B2B (HSPDE4B2B) exists in both a low-and a high-affinity state that bind (R)-rolipram with K-d'S Of ca. 500 and 1 nM, respectively [Rocque, W. J., Tian, G., Wiseman, J. S., Holmes, W. D., Thompson, I. Z., Willard. D. Il., Patel, I. R., Wisely, G. B., Clay, W. C., Kadwell, S. H., Hoffman, C. R., and Luther, M. A. (1997) Biochemistry 36, 14250-14361]. Since the tissue distribution of the two isostates may be significantly different, development of inhibitors that effectively inhibit both forms may be advantageous pharmacologically. In this study, enzyme inhibition and binding of HSPDE4B2B by (R*,R*)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate (1), a novel inhibitor of phosphodiesterase 4 (PDE 4), were investigated Binding experiments demonstrated high-affinity binding of. to HSPDE4B2B with a stoichiometry of 1:1. Inhibition of PDE activity showed only a single transition with an observed K-i similar to the apparent K-d determined by the binding experiments. Deletional mutants of HSPDE4B2B, which have been shown to bind (R)-rolipram with low affinity, were shown to interact with 1 with high affinity, indistinguishable from the results obtained with the full-length enzyme. Bound 1 was completely displaced by (R)-rolipram, and the displacement showed a biphasic transition that resembles the biphasic inhibition of HSPDE4B2B by (R)-rolipram. Theoretical analysis of the two transitions exemplified in the interaction of (R)-rolipram with HSPDE4B2B indicated that the two isostates were nonexchangeable. Phosphorylation at serines 487 and 489 on HSPDE4B2B had no effect on the stoichiometry of binding, the affinity for binding, or the inhibition of the enzyme by 1. These data further illustrate the presence of two isostates in PDE 4 as shown previously for (R)-rolipram binding and inhibition. In contrast to (R)-rolipram, where only one of the two isostates of PDE 4 binds with high affinity, 1 is a potent, dual inhibitor of both of the isostates of PDE 4. Kinetic and thermodynamic models describing the interactions between the nonexchangeable isostates of PDE 4 and its ligands are discussed.
引用
收藏
页码:6894 / 6904
页数:11
相关论文
共 23 条
[1]  
BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1
[2]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[3]   MODULATION OF INFLAMMATION AND IMMUNITY BY CYCLIC-AMP [J].
BOURNE, HR ;
LICHTENSTEIN, LM ;
MELMON, KL ;
HENNEY, CS ;
WEINSTEIN, Y ;
SHEARER, GM .
SCIENCE, 1974, 184 (4132) :19-28
[4]  
FARBER DB, 1991, PROG CLIN BIOL RES, V362, P67
[5]   PHYSICAL AND CHEMICAL PROPERTIES OF NUCLEIC ACIDS [J].
FELSENFE.G ;
MILES, HT .
ANNUAL REVIEW OF BIOCHEMISTRY, 1967, 36 :407-&
[6]   CYCLIC AMP-DEPENDENT REGULATION OF LIPID MEDIATORS IN WHITE CELLS - A UNIFYING CONCEPT FOR EXPLAINING THE EFFICACY OF THEOPHYLLINE IN ASTHMA [J].
KUEHL, FA ;
ZANETTI, ME ;
SODERMAN, DD ;
MILLER, DK ;
HAM, EA .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1987, 136 (01) :210-213
[7]  
LEE HR, 1991, J THORAC CARDIOV SUR, V102, P246
[8]   Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase [J].
Lenhard, JM ;
Kassel, DB ;
Rocque, WJ ;
Hamacher, L ;
Holmes, WD ;
Patel, I ;
Hoffman, C ;
Luther, M .
BIOCHEMICAL JOURNAL, 1996, 316 :751-758
[9]  
MICHAELI T, 1993, J BIOL CHEM, V268, P12925
[10]  
MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201